JP7094700B2 - 喀痰試料中のバイオマーカーとしての細胞外遊離ヌクレオソームの使用 - Google Patents

喀痰試料中のバイオマーカーとしての細胞外遊離ヌクレオソームの使用 Download PDF

Info

Publication number
JP7094700B2
JP7094700B2 JP2017568274A JP2017568274A JP7094700B2 JP 7094700 B2 JP7094700 B2 JP 7094700B2 JP 2017568274 A JP2017568274 A JP 2017568274A JP 2017568274 A JP2017568274 A JP 2017568274A JP 7094700 B2 JP7094700 B2 JP 7094700B2
Authority
JP
Japan
Prior art keywords
extracellular free
nucleosome
epigenetic
sputum
nucleosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017568274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529931A5 (enExample
JP2018529931A (ja
Inventor
ミカレフ ジャコブ
ヘルゾグ マリエレ
Original Assignee
ベルジアン ボリション エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベルジアン ボリション エスアールエル filed Critical ベルジアン ボリション エスアールエル
Publication of JP2018529931A publication Critical patent/JP2018529931A/ja
Publication of JP2018529931A5 publication Critical patent/JP2018529931A5/ja
Application granted granted Critical
Publication of JP7094700B2 publication Critical patent/JP7094700B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017568274A 2015-07-01 2016-07-01 喀痰試料中のバイオマーカーとしての細胞外遊離ヌクレオソームの使用 Active JP7094700B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1511512.4A GB201511512D0 (en) 2015-07-01 2015-07-01 Use of cell-free nucleosomes as biomarkers
GB1511512.4 2015-07-01
PCT/GB2016/051994 WO2017001863A1 (en) 2015-07-01 2016-07-01 Use of cell-free nucleosomes as biomarkers in sputum samples

Publications (3)

Publication Number Publication Date
JP2018529931A JP2018529931A (ja) 2018-10-11
JP2018529931A5 JP2018529931A5 (enExample) 2019-08-15
JP7094700B2 true JP7094700B2 (ja) 2022-07-04

Family

ID=53872486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017568274A Active JP7094700B2 (ja) 2015-07-01 2016-07-01 喀痰試料中のバイオマーカーとしての細胞外遊離ヌクレオソームの使用

Country Status (7)

Country Link
US (1) US20180306804A1 (enExample)
EP (1) EP3317671B1 (enExample)
JP (1) JP7094700B2 (enExample)
CN (1) CN108450000A (enExample)
ES (1) ES2772701T3 (enExample)
GB (1) GB201511512D0 (enExample)
WO (1) WO2017001863A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019228625B2 (en) * 2018-03-01 2024-11-07 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes
US11154240B2 (en) 2019-04-02 2021-10-26 Kpn Innovations Llc Methods and systems for utilizing diagnostics for informed vibrant constitutional guidance
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
BR112022010774A2 (pt) * 2019-12-02 2022-08-23 Belgian Volition Srl Uso de nucleossomos livres de células como biomarcadores
US11289206B2 (en) 2020-06-02 2022-03-29 Kpn Innovations, Llc. Artificial intelligence methods and systems for constitutional analysis using objective functions
US12176108B2 (en) 2020-06-02 2024-12-24 Kpn Innovations Llc Artificial intelligence methods and systems for constitutional analysis using objective functions
US11211158B1 (en) 2020-08-31 2021-12-28 Kpn Innovations, Llc. System and method for representing an arranged list of provider aliment possibilities
GB202310137D0 (en) * 2023-07-03 2023-08-16 Belgian Volition Srl Method for the detection of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012013955A1 (en) 2010-07-28 2012-02-02 Singapore Volition Pte. Limited Method for detecting the presence of a gynaecological growth
WO2014131841A1 (en) 2013-02-28 2014-09-04 Singapore Volition Pte Limited Method for detecting histone modifications in nucleosomes
JP2014529405A (ja) 2011-09-01 2014-11-13 シンガポールボリション ピーティーイーリミテッド ヒストン変種含有ヌクレオソーム検出法
JP2014531573A (ja) 2011-09-01 2014-11-27 シンガポール ボリション ピーティーイー リミテッド ヌクレオチド含有ヌクレオソーム検出法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229772B1 (en) * 1998-03-18 2007-06-12 Roche Diagnostics Gmbh Detection of apoptotic products
SG10201604081YA (en) * 2011-12-07 2016-07-28 Singapore Volition Pte Ltd Method for detecting nucleosome adducts
WO2015048535A1 (en) * 2013-09-27 2015-04-02 Natera, Inc. Prenatal diagnostic resting standards

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012013955A1 (en) 2010-07-28 2012-02-02 Singapore Volition Pte. Limited Method for detecting the presence of a gynaecological growth
JP2014529405A (ja) 2011-09-01 2014-11-13 シンガポールボリション ピーティーイーリミテッド ヒストン変種含有ヌクレオソーム検出法
JP2014531573A (ja) 2011-09-01 2014-11-27 シンガポール ボリション ピーティーイー リミテッド ヌクレオチド含有ヌクレオソーム検出法
WO2014131841A1 (en) 2013-02-28 2014-09-04 Singapore Volition Pte Limited Method for detecting histone modifications in nucleosomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lung Cancer Epigenetics: Emerging Biomarkers，Biomarkers in Medicine，2013年，Vol.7, No.1，49-58

Also Published As

Publication number Publication date
EP3317671A1 (en) 2018-05-09
US20180306804A1 (en) 2018-10-25
GB201511512D0 (en) 2015-08-12
HK1255151A1 (en) 2019-08-09
ES2772701T3 (es) 2020-07-08
CN108450000A (zh) 2018-08-24
JP2018529931A (ja) 2018-10-11
EP3317671B1 (en) 2019-11-13
WO2017001863A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
JP7094700B2 (ja) 喀痰試料中のバイオマーカーとしての細胞外遊離ヌクレオソームの使用
US11193939B2 (en) Method for detecting nucleosome adducts
JP2014531573A (ja) ヌクレオチド含有ヌクレオソーム検出法
JP2014529405A (ja) ヒストン変種含有ヌクレオソーム検出法
KR102442803B1 (ko) 결장직장암에 대한 복합 테스트
EP2962112B1 (en) Method for predicting therapy efficacy using nucleosome structure biomarkers
JP2024504105A (ja) 肺癌の検出のための方法
EP3317672B1 (en) Use of cell-free nucleosomes as biomarkers in fecal samples
HK1255151B (en) Use of cell-free nucleosomes as biomarkers in sputum samples
HK40083883A (en) Method for detecting nucleosome adducts
HK1255090B (en) Use of cell-free nucleosomes as biomarkers in fecal samples
HK1255090A1 (en) Use of cell-free nucleosomes as biomarkers in fecal samples
HK1249176B (en) Method for detecting nucleosome adducts
HK1202926B (en) Method for detecting nucleosome adducts

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220330

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220330

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220408

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220622

R150 Certificate of patent or registration of utility model

Ref document number: 7094700

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250